menu
    • menu
    [{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Pandion Therapeutics \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"Il-2 mutein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"PT101","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"PT001","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"IL-2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8500000000000001,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"PT001","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"PT627","moa":"PD-1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Pandion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8500000000000001,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck"}]

    Find Clinical Drug Pipeline Developments & Deals by Pandion Therapeutics

    Menu

    Pandion Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $1,850.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Completes Acquisition of Pandion Therapeutics

                            Details : Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.

                            Brand Name : PT101

                            Molecule Type : Large molecule

                            Upfront Cash : $1,850.0 million

                            April 01, 2021

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $1,850.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT627

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

                            Details : Under the terms of the agreement, Pandion will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials.

                            Brand Name : PT627

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 16, 2021

                            Lead Product(s) : PT627

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $1,850.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck to Acquire Pandion Therapeutics

                            Details : Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.

                            Brand Name : PT101

                            Molecule Type : Large molecule

                            Upfront Cash : $1,850.0 million

                            February 25, 2021

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $1,850.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycopyrronium Bromide

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pandion Therapeutics Presents Preclinical Data on Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Di...

                            Details : The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.

                            Brand Name : PT001

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            February 22, 2021

                            Lead Product(s) : Glycopyrronium Bromide

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycopyrronium Bromide

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseas...

                            Details : Pandion utilizes its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform to create antibody-based candidates that target known control nodes in the immune system.

                            Brand Name : PT001

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            October 28, 2020

                            Lead Product(s) : Glycopyrronium Bromide

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Pandion Therapeutics Raises $75 million IPO

                            Details : Funds will be used in company's lead asset, PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, designed to selectively expand regulatory T cells systemically without activating proinflammatory cells.

                            Brand Name : PT101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 29, 2020

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON™ Platfo...

                            Details : Patent protects foundational intellectual property and pioneering work on Pandion’s therapeutic autoimmune regulatory protein (TALON) drug design platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 09, 2020

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Access Biotechnology

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Pandion Raises $80 Million Series B to Advance Autoimmune Therapies

                            Details : Proceeds to support advancement of pipeline of modular proteins and bifunctional antibodies for autoimmune diseases, including lead clinical-stage IL?2 mutein program.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 01, 2020

                            Lead Product(s) : PT101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Access Biotechnology

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101

                            Details : Trial to evaluate safety and tolerability of PT101, as well as expansion of regulatory T cells.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 24, 2020

                            Lead Product(s) : PT101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pandion Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibodies

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : Ligand Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

                            Details : Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 13, 2020

                            Lead Product(s) : Antibodies

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : Ligand Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth